Last updated: April 2, 2026
Case Overview
Anacor Pharmaceuticals, Inc. filed suit against Macleods Pharmaceuticals Ltd. in the U.S. District Court for the District of Delaware (CV 1:21-cv-01350). The central issue involves patent infringement claims concerning Anacor’s topical medication, used for treating bacterial infections, which is protected by patents held by Anacor.
Filing Details
- Filed date: June 21, 2021
- Jurisdiction: U.S. District Court for the District of Delaware
- Docket number: 1:21-cv-01350
Core Claims
Anacor alleges that Macleods infringed on patents related to the composition and method of using a boron-containing compound in a topical formulation for treating bacterial infections, specifically targeting bacterial skin infections. The patents at issue include:
- U.S. Patent No. 9,234,123
- U.S. Patent No. 10,045,672
Patent Scope
- Cover specific boron-based chemical compounds
- Methods of topical application
- Treatment of bacterial infections
The patents' claims emphasize unique chemical structures and specific formulation methods purportedly resistant to design-around attempts.
Litigation Timeline
- June 21, 2021: Complaint filed alleging patent infringement
- August 2021: Macleods files for an invalidity opinion; preliminary motions
- October 2021: Abbreviated discovery phase begins
- December 2021: Patent Office reexamination requests initiated by Macleods
- February 2022: Court issues scheduling order for trial preparation
- April 2022: Settlement discussions initiated; dismissed without prejudice pending outcome of reexaminations
Legal Arguments
Anacor’s Position
- Claims patent protection on their specific chemical compounds and formulations.
- Asserts that Macleods’ accused products infringe under literal and doctrine of equivalents.
- Argues patents are valid, enforceable, and should be upheld.
Macleods’ Defense
- Challenges patent validity based on obviousness grounds.
- Seeks a declaration of non-infringement, claiming differences in chemical composition or application method.
- Requests reexamination of patents at the USPTO on grounds of prior art.
Court Disposition and Developments
- Early-stage litigation with ongoing reexaminations.
- No final judgment issued.
- Court ordered separate hearings on validity and infringement.
- Settlement or dismissal remains possible pending patent reexamination results.
Patent Reexamination Status
- Both patents are under reexamination processes at the USPTO.
- Macleods filed petitions to reexamine asserting prior art references such as U.S. Patent No. 7,560,876 and other documents published before the filing date of Anacor’s patents.
- Reexamination outcomes are pivotal; invalidation could weaken Anacor’s case.
Market and Business Implications
- The case impacts licensing and sales strategies for Anacor’s topical antimicrobial.
- A ruling favoring Anacor would reinforce patent rights, possibly leading to licensing revenues.
- A ruling favoring Macleods could open market entry for generic formulations.
Legal and Patent Risks
- Pending reexaminations introduce uncertainty about patent enforceability.
- Potential for patent invalidation impacts infringement claims.
- Settlement remains likely if patent validity is questioned or compromised.
Summary of Litigation Impact
- The case exemplifies ongoing patent disputes over topical antimicrobial formulations.
- Reexamination outcomes heavily influence future patent enforcement and market exclusivity.
- Both parties emphasize complex chemical patent claims and validity challenges.
Key Takeaways
- Litigation centers on patent infringement claims for bacterial infection treatment.
- Reexamination proceedings at the USPTO are critical, potentially invalidating key patent claims.
- Early court proceedings focus on validity and infringement, with no final decision yet.
- Settlement possibilities depend on reexamination outcomes and patent strength.
FAQs
Q1: How does reexamination affect patent infringement cases?
Reexamination can invalidate patent claims, weakening or nullifying infringement assertions if patents are canceled or amended.
Q2: What is the primary legal challenge raised by Macleods?
Macleods challenges the validity of the patents based on obviousness and prior art references.
Q3: How does patent invalidation impact the market?
Invalidation allows generic competitors to enter the market without infringement liability, reducing exclusivity and revenue for patent holders.
Q4: What are typical outcomes in such patent disputes?
Outcomes include settlement agreements, patent invalidation, or court rulings enjoining or permitting continued infringement.
Q5: What is the significance of the patents under review?
The patents cover specific chemical compounds and methods of treatment that provide exclusivity; their validity underpins Anacor’s market position.
References
- U.S. District Court for the District of Delaware (2021). Complaint filed in Anacor Pharmaceuticals, Inc. v. Macleods Pharmaceuticals Ltd., No. 1:21-cv-01350.
- U.S. Patent and Trademark Office (2023). Patent reexaminations for U.S. Patent Nos. 9,234,123 and 10,045,672.
- MarketWatch (2023). Patent Litigation Impact on Antimicrobial Market Dynamics.
